Date: 22-Jul-2020

Mylan Launches Remdesivir In India Under The Brand Name DESREM For Covid-19 Treatment

Global pharmaceutical company Mylan today launched Remdesivir in India under the brand name DESREM, the company announced.

The drug is approved for the treatment of suspected or laboratory confirmed incidences of Covid-19 in adults and children hospitalised with severe infection.

The company also launched a helpline where patients and healthcare practitioners can access information about Mylan’s Remdesivir and its availability.

The first batch of Mylan’s generic remdesivir was released today. The company said it will continue to increase its supply across the country in the wake of the rising demand for the drug.

“Patients and healthcare practitioners can access information about the availability of DESREM in India through Mylan’s 24/7 national helpline number, +91.78299.80066,” the company said in the release.

Mylan is manufacturing the drug in its injectable facility in Bangalore, which will work to service the demand in India and other export markets, the company further said.

“In the wake of increasing cases of COVID-19 across India, Mylan remains committed to continue its efforts in the fight against the pandemic. With the launch of DESREMTM and our national 24/7 COVID-19 helpline, we aim to enhance access to this critical medicine, used for treating adults and children with severe presentations of Covid-19. At Mylan, we believe we have a responsibility to help make the world a better place and the entire team at Mylan has stepped up in this time of need to serve patients and deliver better health for a better world, said Rakesh Bamzai, President, India and Emerging Markets.

So far in India remdesivir has been launched by Hetero Labs and Cipla.